

RECORDATI: PUBLICATION OF THE ABSTRACT OF THE SHAREHOLDERS' AGREEMENTS

Milan, 11 December 2018 – Recordati S.p.A. announces that, based on the information received from the parties, on 6 December 2018 Rossini Luxembourg S.à r.l. (“**Lux Equityco**”), Rossini Holdings S.à r.l. (“**CVC Luxco**”) and Rossini Co-Invest GP Limited entered into a shareholders’ agreement with Finance Street SSMA C.V., AlInvest LIVE Co C.V., ACIF VII C.V., ACIF (Euro) VII C.V., AG Co-Investment C.V., AJ Co C.V., AlInvest GA Co 2018 C.V. and APSS Co-Investment C.V. (the “**AlInvest Shareholders’ Agreement**”). On the same date, Lux Equityco, CVC Luxco and Rossini Co-Invest GP Limited entered into a shareholders’ agreement with PSP Investments Holding Europe Limited (the “**PSP Shareholders’ Agreement**” and, together with the AlInvest Shareholders’ Agreement, the “**Shareholders’ Agreements**”). The Shareholders’ Agreements relate to the corporate governance of Recordati S.p.A., FIMEI S.p.A. and Lux Equityco, as well as to preventive consultation obligations and limits to the transfer of the shares of Lux Equityco and directly or indirectly controlled entities.

In accordance with applicable laws and regulations, it is hereby announced that the abstract of the Shareholders’ Agreements is available on the website of Recordati at www.recordati.it, Corporate Governance section, and on the centralized storage mechanism 1Info (www.1Info.it). The essential information relating to the same shareholders’ agreement is also published on Recordati’s website www.recordati.it pursuant to article 122 of Italian Legislative Decree No. 58/1998 and article 130 of Consob Issuers’ Regulation. The abstract of the Shareholders’ Agreements was also published on the date hereof on the national newspaper “Il Sole 24 Ore” (year 154°, No. 341).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745

e-mail: norismorano@studionorisemorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832